• 제목/요약/키워드: Hcc-1

검색결과 353건 처리시간 0.025초

암환자 169명의 사상 체질 의학적 분포 연구 (Study on Distribution of Sasang Constitution among 169 Cancer Patients)

  • 이종훈;방선휘;유화승;조정효;이연월;조종관;손창규
    • 대한한의학회지
    • /
    • 제28권3호통권71호
    • /
    • pp.138-143
    • /
    • 2007
  • Objective : This study aimed to investigate differential cancer incidence among Sasangin comparing to healthy subjects in the Republic of Korea. Methods : The medical records of 169 patients who had taken diagnosis of Sasang constitution from October 2004 to January 2007 at the East-West Cancer Center in Dunsan Oriental Hospital of Daejeon University were reviewed. Diagnosis was done by Questionnaire for Sasang Constitution ClassificationII (QSCCII). Results : Among the 169 patients, 37.9%, 22.5% and 39.6% belonged to Soyangin, Taeumin and Soeumin, respectively. This is significantly different from the distribution rate of Sasang in amonghealthy subjects (29.1%, 46.9% and 24.0% respectively to Soyangin, Taeumin and Soeumin). This pattern appeared in a similar way among individual cancer analysis: breast cancer (37.5%, 21.9%, 40.6%), colon cancer (41.7%, 20.8% 37.5%), and HCC (35.0%, 20.0%, 45.0%). Stomach cancer typically showed remarkable incidence in Soeumin as high as 50.0% and lung cancer showed in Soyangin as high 46.7%, but it didn't have statistical significance. The mean age of 50.9 years was higher than for healthy people (46.3). Conclusion : Sasang distribution of cancer patients is different from that of healthy subjects. Further study is needed on individual cancers.

  • PDF

Lack of Association of the Cyclooxygenase-2 Gene 8473T>C Polymorphism with Breast Cancer Risk: a Meta-analysis

  • Yang, Xi;Zhao, Fen;Li, Yue-Hua;Huang, Min;Huang, Ying;Yi, Cheng
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권22호
    • /
    • pp.9693-9698
    • /
    • 2014
  • Background: Associations between the 8473T>C polymorphism (rs5275) in the cyclooxygenase-2 (COX-2) gene and breast cancer (BC) risk are still inconclusive and ambiguous. The aim of this meta-analysis was to comprehensively estimate the genetic risk of 8473T>C polymorphism in the COX-2 gene for BC. Materials and Methods: We searched PubMed, Web of Science, Medline, Chinese biomedical (CBM), Weipu, China national knowledge infrastructure (CNKI), and Wanfang databases, covering all publications (last search was updated on Aug 17, 2014). Statistical analyses were performed using Revman 5.3 and STATA 10.0 software. Results: A total of 6,720 cases and 9,794 controls in 12 studies were included in this study. The results indicated no significant associations between the 8473T>C polymorphism of the COX-2 gene and BC risk for the CC+TC vs TT model (pooled odds ratio (OR)=0.97, 95% confidence interval (CI)=0.90-1.03, and p=0.29). On subgroup analysis, we also found that subdivision on ethnicity among Caucasians, Asians and others also revealed no relationship with BC susceptibility. With the study design (CC+TC vs TT), no significant associations were found in either population-based case-control studies (PCC), or hospital-based case-control studies (HCC). Conclusions: This present meta-analysis suggests that the 8473T>C polymorphism in the COX-2 gene is not a conspicuous low-penetrant risk factor for developing BC.

Efficacy of Transarterial Chemoembolization Combined with Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma

  • Xu, Chuan;Lv, Peng-Hua;Huang, Xin-En;Wang, Shu-Xiang;Sun, Ling;Wang, Fu-An
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권14호
    • /
    • pp.6159-6162
    • /
    • 2015
  • Purpose: To evaluate efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in treatment of patients with hepatocellular carcinoma. Materials and Methods: During January 2009 to March 2012, 80 patients with hepatocellular carcinoma underwent TACE, with or without RFA. Alfafetoprotein (AFP) was checked before and after procedure. CT scans were obtained one month after TACE or RFA for all patients to evaluate tumor changes. Complete response+partial response+stable disease (CR+PR+SD)/n were used to assess the disease control rate (DCR). Survival at 3, 6 and 12 months was compared in both groups. Results: AFP levels in TACE + RFA group dropped rapidly, becoming obviously lower than that of the TACE group. In the TACE + RFA group DCR was 93.8%, while only 76.8% in the TACE group. The treatment effect between the two groups was statistically significant (P<0.05) by Ridit analysis. 1 year survival rate in the TACE + RFA group was 92.5%, significantly higher than that of the TACE group at 77.5% (P<0.05). Conclusions: TACE and RFA as combined therapy method for patients with middle and terminal stage HCC gives full play to synergy between the two and improves the therapeutic effect.

압연조건에 따른 AZ31 연주판재의 미세조직 및 기계적 특성 변화 (Effect of Rolling Conditions on Microstructure and Mechanical Properties of HCC AZ31 Alloy Plate)

  • 김영민;천은영;임창동;유봉선;이재현
    • 대한금속재료학회지
    • /
    • 제46권4호
    • /
    • pp.189-198
    • /
    • 2008
  • The changes in microstructure and mechanical properties of AZ31 alloy subjected hot-rolling process were investigated. The AZ31 plates fabricated by horizontal continuous casting process were prepared and have hot-rolled from 30 mm to 1 mm in thickness under different processing conditions. At the rolling temperature of $400^{\circ}C$, little surface and side crack was observed up to 20% reduction rate. As total reduction and reduction rate increase to more than 75% and 20% pass, respectively, Grains were more uniformly refined through overall thickness, and particularly lots of shear bands were appeared to be inclined at less than $20^{\circ}C$ along the rolling direction. Average grain size of less than $5{\mu}m$ and tensile properties of YS ${\geq}$ 250 MPa, UTS ${\geq}$ 300 MPa and El. ${\geq}$ 13% were acquired for hot-rolled AZ31 sheets without post-heat treatment. Maximum intensity of (0002) pole figure was decreased with an increase in reduction rate, indicating the improvement of texture by means of high reduction rate.

HGFK1 is Associated with a Better Prognostis and Reverses Inhibition by Gefitinib in NSCLC Cases

  • Zhou, Xiao-Hui;Tang, Li-Na;Yue, Lu;Min, Da-Liu;Yang, Yi;Huang, Jian-An;Shen, Zan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제13권4호
    • /
    • pp.1457-1461
    • /
    • 2012
  • Purpose: Non small cell lung cancer (NSCLC) is the leading worldwide source of cancer-related deaths. Although some drugs targeting EGFR mutations have been developed, most advanced cases are still incurable. New targets for anticancer drugs are demanded. The kringle 1 domain of hepatocellular growth factor alpha chain (HGFK1) is a potent anti-angiogenesis factor. It has also emerged as a potential anticancer factor in hepatocellular carcinoma (HCC). The expression of HGFK1 protein in patients with NSCLC has not been reported to date. Method: Here, we assessed HGFK1 expression by Western blotting in 103 cases with advanced NSCLC to investigate the impact of HGFK1 on survival. Results: Results revealed 33 (30.1%) patients were classified as high expressors, this being significantly associated with less remote metastasis (P = 0.002) but not with lymph node metastasis (P = 0.062). There was also a significant association between HGFK1 expression and tumor size (P = 0.025) as well as clinical stage (P = 0.012). Kaplan-Meier survival analysis showed that both overall survival (OS) and progression free survival (PFS) of patients with HGFK1 expression were longer than those of patients without HGFK1 expression (P = 0.004 and P = 0.001 respectively). HGFK1 reversed gefitinib inhibition in the resistent NSCLC cell line A431/GR but did not inhibit the proliferation of NSCLC cells A431 and A431/GR directly. Reversion of gefitinib inhibition in A431/GR cells by HGFK1 was related to decreased phosphorylation of ERK and STAT5. Conclusions: HGFK1 may be a useful prognostic factor of advanced NSCLC patients and a potential drug for gefitinib resistant patients.

비소세포폐암 세포주에서 pemetrexed의 세포독성과 유전학적 다형성과의 상관성 조사 (Association of Genetic Variations with Pemetrexed-Induced Cytotoxicity in Non-Small Cell Lung Cancer Cells)

  • 윤성애;최정란;김정오;신정영;장향하;강진형
    • 생명과학회지
    • /
    • 제20권1호
    • /
    • pp.103-112
    • /
    • 2010
  • 페메트렉시드(pemetrexed, $alimta^{(R)}$)는 중피종(mesothelioma)과 비소세포폐암 (non-small cell lung cancer)을 비롯한 다양한 암종에서 엽산(folate) 대사과정에 관여하는 대사물질의 활성을 억제하여 항암효능을 나타낸다. 다중표적 항암제 (multitargeted antifolate)인 pemetrexed는 엽산의 세포내 주요 이동통로인 reduced folate carrier(RFC)를 통해 세포 내로 유입된 후 folylpolyglutamate synthetase (FPGS)에 의해 폴리글루타민산염(polyglutamate) 유도체로 활성되고 thymidylate synthase (TS)와 dihydrofolate reductase (DHFR)를 표적하는 것으로 알려져 있다. 조직형이 서로 다른 비소세포폐암 세포주를 선정하여 pemetrexed의 대사과정에 관여하는 유전자들의 단일염기서열 다형성을 조사하고, mRNA와 단백질의 발현 정도를 비교하여 pemetrexed의 세포독성 효과와의 상관성을 분석하였다. 4개의 비소세포폐암 세포주인 A549, PC14, HCC-1588과 H226에서 RFC, FPGS, TS와 DHFR의 유전형을 조사하였다. Pemetrexed의 약물의 감수성을 알아보기 위해 real-time PCR과 Western blot 방법으로 mRNA 발현과 단백질 발현 정도를 비교하였고, SRB 법으로 약물에 대한 세포독성 효과를 측정했다. PC14 세포주와 H226 세포주에서는 약물처리 전 RFC와 FPGS의 mRNA 발현이 높은 것으로 나타났고, $IC_{50}$값이 각각 $0.08{\pm}0.01\;uM$$0.07{\pm}0.01\;uM$로 pemetrexed에 대한 감수성이 높은 것을 알 수 있었다. A549 세포주에서 TS의 유전형이 2R/2R일 때 mRNA발현이 증가하고 pemetrexed의 약물 저항성과 관련이 있었다. 반면, TS의 유전형이 3R/3R로 나타난 H226에서는 mRNA 발현이 낮은 것을 알 수 있었지만 pemetrexed의 높은 감수성과 관련이 있었다. 세포주 모두에서 pemetrexed 약물처리 후 DHFR의 mRNA 발현은 약물처리 전보다 낮아지는 경향을 보였지만 단백질 발현은 오히려 증가하는 상반된 결과를 보였다. 또한 DHFR 프로모터에 위치한 -1726C>T, -1188A>C SNP는 서로 연쇄 불평형 상태(linkage disequilibrium, LD)에 있었다. 연구결과에서 pemetrexed의 세포독성 효과는 약물 대사과정에 관여하는 여러 분자들의 유전형과 발현 정도에 의해 결정되는 것을 알 수 있었고, 다양한 분석결과를 토대로 항암효능을 평가하는 것이 필요하다고 생각된다.

절제 불가능한 원발성 간암의 온열 및 방사선 병용 요법 (Combined Radiotherapy and Hyperthermia for Nonresectable Hepatocellular Carcinoma)

  • 성진실;노준규;서창옥;김귀언;한광협;이상인;노재경;최홍재;김병수
    • Radiation Oncology Journal
    • /
    • 제7권2호
    • /
    • pp.247-257
    • /
    • 1989
  • 절제 불가능한 원발성 간암은 여러 가지 다양한 치료법의 시도에도 불구하고 그 예후는 극히 불량하다. 이에 본 저자들은 온열요법에 대한 축적된 경험을 바탕으로 1988년 4월부터 7월까지 본과에 내원한 30명 의 절제 불가능한 원발성 간암 환자들에 대하여 온열 및 방사선 병용요법을 시행하였다. 방사선치료는 일일 조사량 180 cGy씩 3. 5주에 3060 cGy를 조사하였고 온열요법은 8 MHz 유전형온열치료기 (Thermotron RF-8, Cancermia)를 사용하여 주 2회씩 총 5회 시행하되 순서는 방사선 치료를 먼저 한 후 30분 이내에 온열요법이 30~60분간 시행되었다. 그 결과 부분반응이 12예에서 관찰되었고(40%), 증상의 호전이 28예 중 22예에서 관찰되었다(78.6%), 종양의 반응을 예측할 수 있는 인자로서는 형태학적 유형이 가장 유의하게 나타났다(single massive: 10/14, 71.4%, diffuse infiltrative: 2/10, 20% : multinodular : 0/6, 0%, p<0.005). 치료로 인한 심각한 부작용은 관찰되지 않았다. 1년 생존율은 34%였고 정중앙 생존기 간은 6.5개월이었다. 부분반응을 보인 환자군의 생존율 및 정중앙 생존 기간은 각각 50%, 11개월로서 반응을 보이지 않은 환자군의 22%, 5개월과 비교해 볼 때 정중앙 생존기간의 차이가 통계적으로 유의하였다.(p<0.05). 결론적으로 온열 및 방사선 병용요법은 절제 불가능한 원발성 간암의 증상호전 및 국소적 치료에 효과가 있는 것으로 생각되며 생존율 및 부작용 등에 관해서는 앞으로 연구가 더 진행되어야 할 것으로 생각된다.

  • PDF

TCP10L synergizes with MAD1 in transcriptional suppression and cell cycle arrest through mutual interaction

  • Shen, Suqin;Zuo, Jie;Feng, Huan;Bai, Meirong;Wang, Chenji;Wei, Youheng;Li, Yanhong;Le, Yichen;Wu, Jiaxue;Wu, Yanhua;Yu, Long
    • BMB Reports
    • /
    • 제49권6호
    • /
    • pp.325-330
    • /
    • 2016
  • T-complex protein 10A homolog 2 (TCP10L) was previously demonstrated to be a potential tumor suppressor in human hepatocellular carcinoma (HCC). However, little is known about the molecular mechanism. MAX dimerization protein 1 (MAD1) is a key transcription suppressor that is involved in regulating cell cycle progression and Myc-mediated cell transformation. In this study, we identified MAD1 as a novel TCP10L-interacting protein. The interaction depends on the leucine zipper domain of both TCP10L and MAD1. TCP10L, but not the interaction-deficient TCP10L mutant, synergizes with MAD1 in transcriptional repression, cell cycle G1 arrest and cell growth suppression. Mechanistic exploration further revealed that TCP10L is able to stabilize intracellular MAD1 protein level. Consistently, the MAD1-interaction-deficient TCP10L mutant exerts no effect on stabilizing the MAD1 protein. Taken together, our results strongly indicate that TCP10L stabilizes MAD1 protein level through direct interaction, and they cooperatively regulate cell cycle progression.

MACC1 Expression Correlates with PFKFB2 and Survival in Hepatocellular Carcinoma

  • Ji, Dong;Lu, Zhong-Tang;Li, Yao-Qing;Liang, Zhe-Yong;Zhang, Peng-Fei;Li, Chao;Zhang, Jun-Li;Zheng, Xin;Yao, Ying-Min
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권2호
    • /
    • pp.999-1003
    • /
    • 2014
  • Objective: To validate the relationship between MACC1 and 6-phosphofructo-2-kinase/fructose 2, 6 bisphosphatase (PFKFB2) expression as well as its clinicopathological features and prognostic significance in hepatocellular carcinoma. Methods: By using immunohistochemistry, we investigated the MACC1 and PFKFB2 protein expression in 60 pairs of hepatocellular carcinoma and corresponding non-tumor tissues. Using the Mann-Whitney U test, the Chi-square test, Kaplan-Meier survival analysis, Cox proportional hazard regression analysis and Spearman analysis, we studied the relationship between MACC1 and PFKFB2 protein expression and postoperative overall survival (OS) of the HCC patients. Results: MACC1 and PFKFB2 positive staining rates were significantly higher in hepatocellular carcinoma than in the corresponding nontumor tissues (P=0.012 and 0.04, respectively). The clinicopathological features evaluation revealed that positive expression of MACC1 was associated with a high Edmondson classification (P=0.007) and advanced TNM stage (P=0.027). Similar findings were evident for PFKFB2 expression (P=0.002 and P=0.027). MACC1 and PFKFB2 positive expression was associated with a lower OS rate (P=0.004 and 0.03, respectively). Kaplan-Meier survival and Cox proportional hazard regression analyses revealed MACC1 positive expression to be a prognostic factor for postoperative OS, but PFKFB was not. Conclusion: Highly expressed MACC1 and PFKFB2 protein were associated with TNM stage, Edmondson-Steier classification and overall survival. MACC1 may affect tumor metabolism partly through expression and phophorylation of PFKFB2.

환자 자세가 간의 방사선 치료 시 선량에 미치는 영향 (The effect of patient position on dose in radiation therapy of liver cancer)

  • 정원석;김주호;김영재;신령미;오정훈;정건아;조준영;김기철;최태규
    • 대한방사선치료학회지
    • /
    • 제26권1호
    • /
    • pp.1-9
    • /
    • 2014
  • 목 적 : 간암 치료 시 호흡으로 인한 움직임을 최소화하기 위해 환자 체위 변화에서 종양의 움직임과 용적 변화를 분석하고자 하였다. 대상 및 방법 : 간 세포암종(Hepatocellular Carcinoma) 환자 14명의 환자를 대상으로 시행하였다. 바로 누운 자세(Supine position)와 엎드린 자세(Prone position)에서 2가지 방법으로 환자 고정기구를 제작하고 영상을 획득하여 간 종양의 움직임과 용적 그리고 선량을 분석하였다. 결 과 : 바로 누운 자세(Supine position)와 엎드린 자세(Prone position) 에서 표적의 왼쪽-오른쪽(LR, Left-right) 움직임은 평균 $2.76{\pm}1.25mm$, $2.21{\pm}0.93mm$이고, 앞-뒤(AP, Anterior-posterior)와 상하(SI. Superior-inferior) 방향의 움직임은 각각 $4.02{\pm}1.63mm$, $11.56{\pm}3.08mm$, $3.36{\pm}1.17mm$, $7.45{\pm}1.96mm$이었다. 이를 이용한 엎드린 자세(Prone position)에서 치료 용적(Treatment volume)은 감소하였고, 이에 따라 정상간 용적은 증가 하였다. 결 론 : 호흡에 의한 간의 움직임을 최소화함으로써 치료 용적(Treatment volume)의 경계여유를 감소시킬 수 있었다. 즉 환자 자세 변화 특히 엎드린(Prone) 자세는 간의 움직임을 감소 시켜주고 정상 간의 용적을 증가 시킬 수 있을 것으로 사료된다.